Tag: Approval
Novartis Receives European Commission Approval for Rhapsido®, the First Oral Targeted Therapy for Chronic Spontaneous Urticaria
Novartis has officially received European Commission (EC) approval for Rhapsido® (remibrutinib), marking a historic shift in the management of chronic spontaneous urticaria (CSU). Rhapsido...